NJ State Employees Deferred Compensation Plan’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

NJ State Employees Deferred Compensation Plan’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-4,500	Closed	-$264K	–	487
2023 Q4	$264K	Buy	+4,500	New	+$253K	0.04%	395
2023 Q1	–	Sell	-4,500	Closed	-$204K	–	500
2022 Q4	$204K	Hold	4,500	–	–	0.03%	425
2022 Q3	$314K	Hold	4,500	–	–	0.05%	346
2022 Q2	$302K	Hold	4,500	–	–	0.05%	354
2022 Q1	$370K	Hold	4,500	–	–	0.05%	358
2021 Q4	$660K	Hold	4,500	–	–	0.08%	246
2021 Q3	$796K	Hold	4,500	–	–	0.11%	202
2021 Q2	$727K	Hold	4,500	–	–	0.1%	226
2021 Q1	$771K	Hold	4,500	–	–	0.11%	200
2020 Q4	$988K	Hold	4,500	–	–	0.15%	142
2020 Q3	$747K	Hold	4,500	–	–	0.13%	153
2020 Q2	$514K	Hold	4,500	–	–	0.1%	213
2020 Q1	$346K	Hold	4,500	–	–	0.08%	250
2019 Q4	$580K	Buy	+4,500	New	+$434K	0.1%	228

Other funds holding MRTX

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

NJ State Employees Deferred Compensation Plan's MRTX Position: Q1 2024 in Review

NJ State Employees Deferred Compensation Plan sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 4,500 shares — an estimated $264K sold.

NJ State Employees Deferred Compensation Plan first reported a position in MRTX in Q4 2019 and held it in 14 quarters. The position peaked at $988K in Q4 2020. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

NJ State Employees Deferred Compensation Plan reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
NJ State Employees Deferred Compensation Plan sold 4,500 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $264K.
NJ State Employees Deferred Compensation Plan first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2019 and held it in 14 quarters.
NJ State Employees Deferred Compensation Plan's Mirati Therapeutics, Inc. Common Stock position peaked at $988K in Q4 2020.
2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on NJ State Employees Deferred Compensation Plan's 13F filing for Q1 2024, filed 2 May 2024.